Venezuela devalues its Bolivar; CPG firms adjust outlook
This article was originally published in The Rose Sheet
Executive Summary
U.S. companies with business in Latin America, where growth has continued despite the global recession, are likely to see reduced earnings in Venezuela as the value of the bolivar drops from approximately 2.15 to 2.6 per dollar for essential goods and 4.3 for non-essentials, in accordance with President Hugo Chavez's devaluation of the country's currency. Colgate-Palmolive expects its products to fall into the non-essential category, according to Jan. 11 release. The devaluation won't affect the firm's 2009 results or competitive position, Colgate says. In the first quarter of fiscal 2010, the firm anticipates recording a one-time gain of $60 mil. ($0.12 per share) and ongoing quarterly charges of $0.04 to $0.06 per share related to the devaluation. The Venezuelan market reportedly represents about 9 percent of Colgate's profits. Procter & Gamble, Avon Products and Burt's Bees owner Clorox Co. are also expected to be affected by the devaluation
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.